Classifying Rouge Helps Define Remediation Procedures - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Classifying Rouge Helps Define Remediation Procedures
Identifying and classifying rouge can help to determine CAPA.


Pharmaceutical Technology
Volume 36, Issue 9, pp. 46-47

Rouge is a common phenomenon in water-for-injection (WFI) and clean-steam systems and can often be found in equipment and piping connected to these systems. The root cause of rouging in high-grade stainless steel equipment is a contentious issue among pharmaceutical engineers and definitions of rouge range widely. What is generally agreed is that rouge is a form of surface corrosion that can form on stainless steel when exposed to high-purity water at elevated temperatures. This corrosion can manifest itself as a glazed, immobile discoloration or as a powdery reddish deposit (1).

Opinions on how to investigate and assess the impact of rouge and choose appropriate corrective and preventive actions (CAPA) are diverse and sometimes conflicting. Essentially, however, the quality assurance (QA) specialist or product manager must assure that the equipment is not reactive, additive, or absorptive, as per 21 CFR 211.65(a) (2). Questions to investigate may include:

  • Is this rouged metal a good spot for biofilm development?
  • Is iron oxide particulate present in the final solution?
  • Could iron oxide affect the stability or effectiveness of the product?

Investigating impact


Rouging on a stainless-steel tank. (IMAGES COURTESY OF THE AUTHOR)
The team investigating rouge can collect and analyze existing data from their process. For example, surface roughness (Ra) would have been measured during installation qualification of the WFI still and piping. Further data would be available from the operational and performance qualifications on clean-in-place system tanks. The team can also analyze water testing and monitoring data over the system lifetime, and look at the impurity profile for products made in these tanks or with this WFI. Using quality systems and release criteria from years of operation, investigators have many of the tools needed to assess any potential effect to the product or intermediates from the observed rouge.


Rouging on a water-for-injection pump impeller.
Investigators should first determine whether the observed problem is indeed rouge and not product residue or another type of contamination. If a swab from the surface comes away with reddish-brown residue, the residue can be sent to a laboratory that performs Fourier transform infrared spectroscopy (FTIR) analysis. This analysis will show the presence of iron oxide from a sample of rouge. Close visual inspection should also be used to assure that there is no pitting or flaking in the affected area, which would indicate an advanced level of corrosion beyond the scope of rouging.

If rouge is present, the most critical determination is whether the rouge is additive to the process or not. Is the rouge firmly adhered to the surface of the equipment or could it instead come off into the process stream either slowly or as a result of water hammer or another shock? If the rouge is glazed and smooth in appearance and does not wipe off or is not found on downstream filters or gaskets, then it would be safe to conclude that it is not an additive problem. A second critical determination is whether the rouged location is cleanable. If it is not cleanable, it could be a spot where biofilm could develop, which could impact the process. One should assess the cleanability of the rouged area by comparing the surface roughness to areas with no rouge in the same tank or piece of equipment. A review of any cleaning or monitoring data from the system can be used to corroborate whether the rouge is additive and cleanable.

If, on the other hand, the rouge wipes off easily on a swab or a glove, or is found downstream on filters or gaskets, then it can also be found in the WFI or process stream. The equipment can indeed be said to be "additive, reactive, or absorptive," which is a violation of 21 CFR 211.65(a). In this case, one must investigate the impact of iron oxide particulate in the WFI or other process fluids.

Factors such as dilution or downstream filtration may contribute to an impact assessment. The engineering team can calculate the surface area of equipment effected by rouge and the amount of rouge particulate possible in the system. This calculation may reveal that the dilution factor is so small that no further investigation is needed. WFI added to any critical downstream process will most likely have a sterile filter in line as well. Although rouge particulate may be as small as 10 nm, particulate normally clumps into larger sizes, and is trapped in sterile filters (3). Conductivity, which is a monitored criteria in WFI loops, is not elevated by rouge because the volume and usage of the WFI storage and distribution system is too great in comparison to the volume of iron oxide particulate that could be formed and released into the circulating WFI in a measurable amount.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here